NYXH实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (29 Jun 2024 @ 04:00):
Our systems believe the stock currently is undervalued by 0.09% compare to its pairs and should correct upwards.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions...

Stats
今日成交量	5 149
平均成交量	40 896
市值	239.49M
EPS	$-0.420 ( Q1 \| 2024-03-31 )
下一个收益日期	( $-0.450 ) 2024-08-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.33 (Sector) 42.63 (Industry) 78.56
ATR14	$0.0620 (0.89%)

GCTK 0.50%

GMVDW -1.13%

LUCY 50.00%

LUCYW 2.97%

NXGLW 0.00%

NYXH -0.57%

OMIC -9.33%

POCI 0.51%

相关性 (AI algo v.1.1b): Undervalued: 0.09% $6.98 paired level. (算法实时跟踪最相关股票的变化并提供即时更新)

音量相关性

長: -0.23 (neutral)

短: 0.74 (moderate)

Signal:(46.696) Neutral

Nyxoah S.A. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Nyxoah S.A. 相关性 - 货币/商品

0.27
( neutral )

-0.36
( neutral )

0.00
( neutral )

0.24
( neutral )

-0.41
( neutral )

-0.07
( neutral )

Nyxoah S.A. 财务报表

Annual	2023
营收:	$4.35M
毛利润:	$332 000 (7.64 %)
EPS:	$-1.550

FY	2023
营收:	$4.35M
毛利润:	$332 000 (7.64 %)
EPS:	$-1.550

FY	2022
营收:	$3.08M
毛利润:	$1.93M (62.71 %)
EPS:	$-1.210

FY	2021
营收:	$852 000
毛利润:	$549 000 (64.44 %)
EPS:	$-1.160

Financial Reports:

No articles found.

Nyxoah S.A. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Nyxoah S.A.

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.